Notice2023-13792
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 29, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 124 (Thursday, June 29, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 124 (Thursday, June 29, 2023)]
[Notices]
[Page 42090]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-13792]
[[Page 42090]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. to achieve
expeditious commercialization of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; Michael Shmilovich; <a href="/cdn-cgi/l/email-protection#03706b6e6a6f6c756e436d6a6b2d646c75"><span class="__cf_email__" data-cfemail="285b40454144475e4568464140064f475e">[email protected]</span></a>; telephone: 301-
435-5019. A signed Confidential Disclosure Agreement may be required to
receive any unpublished information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Cannabinoid Receptor Modulating Compounds
Available for licensing and commercial development are potentially
therapeutic compounds for metabolic, inflammatory and fibrotic
disorders. The filed patent applications includes extensive
descriptions of the exemplary molecules and their various constituents.
The cannabinoid receptor mediating compounds can be neutral
antagonists. A CB<INF>1</INF> inverse agonist is a drug that on its own
produces an effect opposite to that of a CB<INF>1</INF> agonist, and is
also able to block the effect of a CB<INF>1</INF> agonist. In contrast,
a CB<INF>1</INF> neutral antagonist can only do the latter (i.e.,
blocking the effect of a CB<INF>1</INF> agonist), but has no effect on
its own. CB<INF>1</INF> inverse agonism is usually documented by the
ability of a drug to decrease GTP[gamma]S binding and/or to increase
adenylate cyclase activity. The compounds may show functional bias for
GTP[gamma]S or [beta]-Arrestin or activity for both GTP[gamma]S and
[beta]-Arrestin. Secondary targets could include, but not limited to,
the enzyme inducible nitric oxide synthase (iNOS) or adenosine
monophosphate kinase (AMPK), as suggested by findings that inhibition
of iNOS or activation of AMPK improves insulin resistance, and reduces
fibrosis and inflammation. The rights pursued claim compounds,
pharmaceutical compositions, and methods of use.
Potential Commercial Applications
<bullet> Pharmaceuticals
<bullet> Cancer therapy
<bullet> Anti-fibrotic therapy
<bullet> Inflammatory and autoimmune disease
Development Stage
<bullet> Early stage
Inventors: Malliga R. Iyer, Ph.D.; Pinaki Bhattacharjee, Ph.D.;
Resat Cinar, PharmD, MBA; George Kunos, M.D., Ph.D.; Szabolcs Dvoracsko
Ph.D., (all of NIAAA).
Intellectual Property: HHS Reference No. E-189-2021-0; U.S.
Provisional Patent Application No. 63/319,642 filed March 14, 2022;
International Patent Application PCT/U2023/014846 filed March 8, 2023.
Licensing Contact: Michael Shmilovich; 301-435-5019;
<a href="/cdn-cgi/l/email-protection#c1aca8a2a9a0a4adefb2a9aca8adaeb7a8a2a981afa8a9efa6aeb7"><span class="__cf_email__" data-cfemail="81ece8e2e9e0e4edaff2e9ece8edeef7e8e2e9c1efe8e9afe6eef7">[email protected]</span></a>.
This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404
to achieve expeditious commercialization of results of federally-funded
research and development.
Dated: June 23, 2023.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2023-13792 Filed 6-28-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 29, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.